• |
  • |
  • |
  • |
Donate

Project

A Phase 2, Randomized, Double-Blind Controlled Study to Evaluate the safety and efficacy of VX-440 combination therapy in subjects aged 12 years...

Center:
Fiscal Year:
2017
Contact Information:
Project Description:
A Phase 2, Randomized, Double-Blind Controlled Study to Evaluate the safety and efficacy of VX-440 combination therapy in subjects aged 12 years and older with cystic fibrosis. Vertex Pharmaceuticals, Inc.
Keyword(s):
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Health-Related Activities
Target Audience:
Children/Adolescents with Disabilities/SHCN
Unserved or Under-served Populations:
Racial or Ethnic Minorities, Disadvantaged Circumstances, Limited English, Geographic Areas
Primary Target Audience Geographic Descriptor:
National
Funding Source:
COVID-19 Related Data:
N/A